providing best matched blood by james aubuchon
TRANSCRIPT
![Page 1: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/1.jpg)
Providing the Best-Matched BloodThe Present and the Future
James P. AuBuchon, MD, FCAP, FRCP(Edin)President & CEO
Professor of Medicine and of Laboratory MedicineUniversity of Washington
Blood Bank of HawaiiTransfusion Medicine Symposium
August 6, 2016
![Page 2: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/2.jpg)
Disclosures
• I have no financial relationships related to this presentation.
• I will not be speaking about any specific commercial product, device, or medication.
• I will not be speaking of any off label use of medications or devices
![Page 3: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/3.jpg)
The Evolution of Matching
ABO
Rh: D, C, c, E, e …
M, N, S, s, P, I, Jka, Jkb, Fya,Fyb, Doa, Dob, Wra, K, k, V, VS,Goa and over 200 others!
![Page 4: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/4.jpg)
What Does Matching Mean to You?
Alloimmunized patient- for current and past specificities- acknowledgement of “responder” status (?)
Inability to perform an antibody screen or crossmatch- e.g., panagglutinin
Chronically transfused patients (prospective matching)
![Page 5: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/5.jpg)
Finding Those Who Need a Better Match
I II III
III + + + - + - -
I - - + - + - +
II + + - + - + -
Reagent Cells' Phenotypes Reactions
I.S. 37C AHGJkaKeEcCD
Antibody Screen for red cell alloantibodies
- - -
- - +
- - -
Antibody identificationUnit screening Unit typingCrossmatching
![Page 6: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/6.jpg)
Finding Those Who Need a Better Match
I II III
III + + + - + - -
I - - + - + - +
II + + - + - + -
Reagent Cells' Phenotypes Reactions
I.S. 37C AHGJkaKeEcCD
Antibody Screen for red cell alloantibodies
- -
- - +
- - +
+
Panagglutinin?Alloantibody “underneath”?
![Page 7: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/7.jpg)
Finding Those Who Need a Better Match
I II III
III + + + - + - -
I - - + - + - +
II + + - + - + -
Reagent Cells' Phenotypes Reactions
I.S. 37C AHGJkaKeEcCD
Antibody Screen for red cell alloantibodies
- -
- 3+
- - 2+
1+
Multiple specificities?
1+
![Page 8: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/8.jpg)
Preventing Alloimmunization
Who?- All patients- Women of child-bearing potential- Chronically transfused patients- “Responders”- WAIHA patients
How?- Pathogen inactivation (?)- Prospective matching
- Limited- Extensive- “Complete”
![Page 9: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/9.jpg)
Who Needs Prevention?Transfused Sickle Cell Disease Patients
Alloimmunization
58%
15%
62% with “unexplained” Rh Abs delayed reactions in one-third
Chou ST et al. Blood 2013; 122:1062-71.
Phenotypically and racially matched donor insufficient to prevent alloimmunization.
High-resolution genotyping: 87% of patients had Rh variants
![Page 10: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/10.jpg)
Drawing courtesy of Suzanne Lentzsch, Columbia University
Multiple Myeloma Plasma Cell
CD38
CD38
Daratumumab (Darzelex™)
Monoclonal Antibody Immunotherapy
NK Cell
![Page 11: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/11.jpg)
CD38
Reagent red cell
Anti-CD38 in patient serum
YAnti-IgG YPositive Ab Screen
“Panagglutinin”but negative DAT
Monoclonal Antibody ImmunotherapyComplications…
About one-third of myeloma patients require RBC transfusions
![Page 12: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/12.jpg)
CD38
Reagent red cell
Anti-CD38 in patient serum
Monoclonal Antibody ImmunotherapyCounteracting the complications…
Cord red cell
Schmidt AE et al. Transfusion 2015;55:2292-3.
![Page 13: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/13.jpg)
CD38
Reagent red cell
Anti-CD38 in patient serum
Monoclonal Antibody ImmunotherapyY
Anti-idiotype antibody
Anti-CD38 in patient serum
Y
Anti-idiotype antibody
Counteracting the complications…
Oostendorp M et al. Transfusion 2015;55:155-62.Lokhorst HM et al. ASCO Meeting Abstr 2013;31(15 Suppl):8512.
![Page 14: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/14.jpg)
CD38
Reagent red cell
Anti-CD38 in patient serum
Monoclonal Antibody ImmunotherapyCounteracting the complications…
DTT
DTT
DTT
Chapuy CI et al. Transfusion 2015;55:1545-54.
![Page 15: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/15.jpg)
CD38
Reagent red cell
Anti-CD38 in patient serum
Monoclonal Antibody ImmunotherapyCounteracting the complications…
K kKpa
Kpb
Jsa
Jsb
Lua
Lub
DoaDob
Yta
Ytb
DTT
DTT Impaired ability to detect antibodies with Kell, Dombrock, Lutheran or Cartwright specificity
Provide units matched for (at least) K
Chapuy CI et al. Transfusion 2015;55:1545-54.
![Page 16: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/16.jpg)
Monoclonal Antibody ImmunotherapyAvoiding the complications…
Before therapy:Document lack of antibodiesPhenotype/Genotype
Panagglutinin but negative DAT:Check historyDemonstrate causeProvide matched RBCs
![Page 17: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/17.jpg)
Wilkinson K et al. Transfusion 2012:52; 381-8.
Is Matching Feasible?
ABO, D, C, c, E, e, K + Fya, Fyb + Jka, Jkb , S, s
Of 70 SCD pts:
from 10,000 donors
![Page 18: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/18.jpg)
One Approach to GenotypingBioArray – Since 2006
Donors: Group O A B≥ 10 donations 8 4
Phenotyping: C/c, E/e automated
Self-identified African-AmericanGenotyping: R1R1, R2R2, RoRo, rr
15,000+ phenotyped donors (35 antigens)
Research Institute USN contract for genotyping research Rotary grant IRL
![Page 19: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/19.jpg)
Passing Along the Information
O negDonor genotyped as C-E-K-Fy(a-b-)Jk(a-b+)
BPAC: November, 2014FDA: February, 2015 (must request variance)
Two separate donations genotyped
![Page 20: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/20.jpg)
Serving 90 hospitals with over 300,000 blood components annually.
![Page 21: Providing Best Matched Blood by James AuBuchon](https://reader035.vdocument.in/reader035/viewer/2022062401/58eefb581a28ab743a8b470f/html5/thumbnails/21.jpg)
Providing the Best-Matched BloodThe Present and the Future
Objectives
Identify two antibody workup situations in which red cell genotyping should be considered.
Name two patient populations that would benefit from prospective phenotype/genotype matched red cells.